Skip to main content
Contact Us
Subscribe
E-Edition
49°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about Biogen Inc
Recent news which mentions Biogen Inc
< Previous
1
2
3
Next >
Thursday's big stock stories: What's likely to move the market in the next trading session
September 25, 2024
Tags
Stock markets
stocks
Micron Technology Inc
From
CNBC.com News
5 things to know before the stock market opens Monday
September 09, 2024
Tags
Technology
Boeing Co
Eisai Co Ltd
From
CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
September 08, 2024
Tags
US: News
Companies
Biogen Inc
From
CNBC.com News
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
August 01, 2024
Tags
Breaking news
Pharmaceuticals
Business
From
CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags
Biotech and Pharmaceuticals
Health care industry
Eisai Co Ltd
From
CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags
Breaking news
Pharmaceuticals
Business
From
CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags
Biotech and Pharmaceuticals
Health care industry
Eli Lilly and Co
From
CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags
Business
Investment Strategy
Stock markets
From
CNBC.com News
Cramer's Lightning Round: Bank of America is a buy
May 10, 2024
Tags
Business
Micron Technology Inc
Investment Strategy
From
CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
Health care industry
Eisai Co Ltd
Earnings
From
CNBC.com News
5 things to know before the stock market opens Monday
April 22, 2024
Tags
Alphabet Inc
Politics
Investment strategy
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Eisai Co Ltd
Eli Lilly and Co
Health care industry
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Biotech and Pharmaceuticals
Health & Science
Biogen Inc
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Eisai Co Ltd
Health care industry
Earnings
From
CNBC.com News
5 things to know before the stock market opens Monday
February 12, 2024
Tags
Coinbase Global Inc
Restaurant Brands International Inc
Verizon Communications Inc
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Health & Science
Business News
Companies
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Biogen Inc
Biotechnology
Companies
From
CNBC.com News
5 things to know before the stock market opens Monday
November 06, 2023
Tags
MGM Resorts International
Business
Walt Disney Co
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Science
Breaking news
Business
From
CNBC.com News
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug
August 07, 2023
Tags
SAGE Therapeutics Inc
Drug approvals
Breaking news
From
CNBC.com News
Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more
July 28, 2023
Tags
New York Community Bancorp Inc
First Solar Inc
Markets
From
CNBC.com News
Stocks making the biggest moves midday: Spotify, RTX, General Electric and more
July 25, 2023
Tags
Market Insider
Alaska Air Group Inc
Zscaler Inc
From
CNBC.com News
Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
July 25, 2023
Tags
Companies
US: News
Biogen Inc
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Eisai Co Ltd
Eli Lilly and Co
Bank of America Corp
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Alzheimer's disease
Pharmaceuticals
Business
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
US: News
Social issues
Biogen Inc
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Biotech and Pharmaceuticals
Eisai Co Ltd
Health care industry
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
First Solar Inc
Alibaba Group Holding Ltd
Eisai Co Ltd
From
CNBC.com News
Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more
July 07, 2023
Tags
Meta Platforms Inc
Costco Wholesale Corp
Economy
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
World Markets
Pharmaceuticals
Asia Markets
From
CNBC.com News
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.